Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes

Cancer Research

Volumn 64, Issue 21, 2004, Pages 8052-8056

  Bendle, Gavin M ^a   Holler, Angelika ^a   Pang, Luke Kwok ^a   Hsu, Stephen ^a,b   Krampera, Mauro ^a,c   Simpson, Elizabeth ^a   Stauss, Hans J ^a,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^c UNIVERSITY OF VERONA   (Italy)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; PROTEIN MDM2;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL KILLING; CELL SPECIFICITY; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TISSUE INJURY; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; T-LYMPHOCYTES, CYTOTOXIC;

EID: 7444232644     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0630     Document Type: Article

References (35)

1. Momand J, Zambetti GP. Mdm-2: "big brother" of p53. J Cell Biochem 1997;64:343-52.
2. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;59:1-7.
3. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003;3:145-60.
4. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94.
5. Yang S, Linette GP, Longerich S, Haluska FG. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J Immunol 2002;169:531-9.
6. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 1996;93:13114-8.
7. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
8. Kessels HW, van Den Boom MD, Spits H, Hooijberg E, Schumacher TN. Changing T cell specificity by retroviral T cell receptor display. Proc Natl Acad Sci USA 2000;97:14578-83.
9. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci USA 2000;97:5387-92.
10. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2:962-70.
11. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999;20:180-3.
12. Dahl AM, Beverley PC, Stauss HJ. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J Immunol 1996;157:239-46.
13. McCoy JL, Fefer A, Glynn JP. Comparative studies on the induction of transplantation resistance in BALB-c and C57BL-6 mice in three murine leukemia systems. Cancer Res 1967;27:1743-8.
14. Restifo NP, Esquivel F, Asher AL, et al. Defective presentation of endogenous antigens by a murine sarcoma, implications for the failure of an anti-tumor immune response. J Immunol 1991;147:1453-9.
15. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-59.
16. Sadovnikova E, Zhu X, Collins SM, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol 1994;6:289-96.
17. Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000;13:265-76.
18. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
19. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus El-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 1989;59:603-14.
20. Feltkamp MC, Vreugdenhil GR, Vierboom MP, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-42.
21. Toes RE, Offringa R, Blom RJ, et al. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 1995;154:3396-405.
22. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995;145:167-77.
23. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
24. Oehen S, Brduscha-Riem K. Naive cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: a pitfall for T cell memory studies? Eur J Immunol 1999;29:608-14.
25. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-9.
26. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002;62:1462-70.
27. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000;191:795-804.
28. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001;2:789-92.
29. Jones LA, Chin LT, Longo DL, Kruisbeek AM. Peripheral clonal elimination of functional T cells. Science 1990;250:1726-9.
30. Rocha B, von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991;251:1225-8.
31. Morahan G, Allison J, Miller JF. Tolerance of class I histocompatibility antigens expressed extrathymically. Nature 1989;339:622-4.
32. Rocha B, Tanchot C, Von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 1993;177:1517-21.
33. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992;4:661-71.
34. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-6.
35. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187:693-702.